Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2003

View Archived Issues

Thalidomide in complex regional pain syndrome

Novel gastric antisecretory drugs under study at Altana Pharma

New series of gamma-secretase inhibitors identified by Merck scientists

5-HT receptor modulators and their use in anxiety, obesity, etc.

Genzyme Biosurgery and Excigen collaborate on gene therapy for cardiac arrhythmias

Schering-Plough presents sulfonamide-based gamma-secretase inhibitors

Italian researchers identify novel antitumor taxanes

NeuTec updates six-month progress of lead compounds

New factor Xa inhibitors synthesized by Merck KGaA

Peptides described with the ability to bind to atherosclerotic lesions

BVT-3498 enters phase II trial for type 2 diabetes

Merck describes new MCH receptor antagonists with utility in obesity

Enrollment under way in pivotal trial of T-67 in hepatocellular carcinoma

Extension planned for phase III trials of RG-1068 in autism

CPMP recommends approval of Busulfex in Europe

IntegraGen identifies therapeutic target in obesity

Targeted Genetics extends HIV vaccine development collaboration

West and Chiron collaborate on nasal diphtheria and tetanus vaccine

Progress on three fronts in OGS/Medarex alliance

Orally active progesterone receptor modulator characterized at Meiji Seika

S-3578: a broad-spectrum parenteral cephalosporin with good anti-MRSA activity

Neuroprotective peptide acts by activating AP-1 pathway

6-Aminoquinolone targeting HIV-1 transcription

FDA approves Somavert for acromegaly

Bayer launches Kinzalmono and Kinzalkomb

Versicor changes corporate name to Vicuron Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...